Table 1.
Baseline characteristics and metabolic profile of people with HIV.
| Variable | Total cohort (n = 282) |
| Age in years | 51 (42; 58) |
| Time since diagnosis (years) (n = 268) | 12 (6; 20) |
| Male | 198 (70.2) |
| Female | 84 (29.8) |
| VCTE | |
| CAP (dB/m) | 248 (214.8; 300) |
| LSM (kPa) | 4.6 (3.8; 5.7) |
| Metabolic comorbidities | |
| BMI (kg/m2) (n = 272) | 25 (22.3; 28.1) |
| Underweight (<18.5 kg/m2) | 9 (3.2) |
| Normal weight (18.5 to <25 kg/m2) | 126 (44.7) |
| Overweight (25 to <30 kg/m2) | 93 (33) |
| Obese (>30 kg/m2) | 44 (15.6) |
| Waist circumference (cm) (n = 270) | 96 (86.8; 104) |
| Male >94 cm | 115 (40.8) |
| Female >80 cm | 71 (25.2) |
| Type 2 diabetes (n = 261) | 30 (10.6) |
| Total cholesterol >200 mg/dl (n = 181) | 91 (32.3) |
| Triglycerides >150 mg/dl (n = 175) | 71 (25.2) |
| HDL-cholesterol: male <40 mg/dl | 39 (13.8) |
| female <50 mg/dl (n = 149) | 13 (4.6) |
| Arterial hypertension (n = 268) | 85 (30.1) |
| Metabolic syndrome | 72 (25.5) |
| Alcohol consumption (n = 282) | |
| Male >20 (g/day) | No: 165 (90.2); yes: 22 (9.8) |
| Female >10 (g/day) | No: 68 (90.7); yes: 7 (9.3) |
| Laboratory values | |
| ALT (U/l) (n = 263) | 24 (18; 32) |
| AST (U/l) (n = 263) | 26 (23; 32) |
| Triglycerides (mg/dl) (n = 175) | 131 (91; 190) |
| Cholesterol (mg/dl) (n = 181) | 200 (174; 226) |
| HDL (mg/dl) (n = 133) | 48 (39; 57.5) |
| LDL (mg/dl) (n = 133) | 120 (102; 144) |
| HbA1c (%) (n = 133) | 5.4 (5.1; 5.7) |
| Uric acid (mg/dl) (n = 146) | 5.5 (4.8; 6.4) |
| Hepatitis serology | |
| Anti-HCV positive (n = 134) | 8 (2.8) |
| HBsAg positive (n = 129) | 4 (1.4) |
| HIV-related parameters and medication (ART) | |
| CDC stage (n = 185) | A: 80 (43.2); B: 47 (16.7); C: 58 (20.6) |
| HIV RNA (n = 274) | |
| Above threshold | 102 (36.2) |
| Below threshold | 172 (61) |
| CD4+ (cells/μl) (n = 266) | 723.5 (515.8; 910.8) |
| >500 cells/μl | 207 (73.4) |
| NRTI | 253 (89.7) |
| TAF as part of ART | 179 (63.5) |
| TDF as part of ART | 31 (11) |
| NNRTI | 62 (22) |
| PI | 41 (14.5) |
| INSTI | 188 (66.7) |
| DTG | 68 (36.2) |
| TAF and INSTI | 124 (44) |
Data are expressed as numbers, median, percentage (%) or interquartile ranges (IQR 25th–75th). ALT, alanine-aminotransaminase; ART, antiretroviral therapy; AST, aspartate-aminotransaminase; CDC, Centres for Disease Control and Prevention; DTG, dolutegravir; HDL, high-density lipoprotein; INSTI, integrase inhibitors; LDL, low-density lipoprotein; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; NRTI, nucleoside reverse-transcriptase inhibitors; NNRTI, nonnucleotide reverse transcriptase inhibitors; PI, protease inhibitors.